Recently, LW402, a next-generation oral JAK1 selective inhibitor independently developed by LWBP, has completed all patient dosing and data collection in a Phase II clinical study on rheumatoid arthritis (RA), and obtained positive results. Blinded clinical data showed that the ACR50 and ACR70 response levels of LW402 were far ahead of all RA therapeutic drugs that have been approved, and it is expected that the ACR70 data of the target dose can reach an astonishing 60% or more.
LW402 has a rapid onset of efficacy, significantly improving inflammation-related efficacy within one week, with clinical outcomes significantly better than marketed products. The safety profile of LW402 has been further validated in phase II studies(RA, AD), with no SAEs related to LW402, which is significantly better than that of marketed products.
LW402 has applied its own IP rights and PCT international patent protection, and the relevant IP rights cover China, North America, the European Union and Asia-Pacific and other major countries and regions around the world. In the future, LW402 will be commercialised for multiple indications with global collaborations through Licensing Out.
About LWBP
Founded in 2012, LWBP is an innovative drug R&D company led by world-renowned chemical drug experts. The company is committed to independently developing world-leading innovative drugs with global intellectual property rights to meet unmet clinical needs. Focusing on the development and industrialization of innovative drugs in the fields of antiviral, tumour immunity and autoimmune diseases, the company has carried out a number of self-developed small molecule drugs (FIC, first in class), and a number of them have entered the clinical trial stage. The core products have reached the international leading level in terms of clinical evaluation indexes, and are expected to become a major breakthrough in the relevant fields(New Class, First-in-Class)
About LW402
LW402 is a next-generation oral JAK1 inhibitor independently developed by LWBP for the treatment of autoimmune diseases such as atopic dermatitis, rheumatoid arthritis, vitiligo and so on. LW402 is a more efficient and safer JAK1 selective inhibitor, which can effectively control the progression of autoimmune diseases by inhibiting cytokine signals through blocking the JAK-STAT signalling pathway, and is expected to become a new and important therapy for the treatment of autoimmune diseases. LW402 has the potential to become the best choice for the treatment of rheumatoid arthritis, atopic dermatitis, vitiligo, etc., with a promising prospect for commercialisation.
